RGNX is focused on developing, commercializing and licensing recombinant adeno-associated virus gene therapy with a proprietary delivery platform to treat rare diseases. RGNX is commercializing gene therapy products administered directly into the body, or in vivo, based on a NAV Technology Platform. Its NAV Technology Platform is currently being applied in the development of 23 product candidates for a variety of diseases, Regenxbio said, with exclusive rights to over 100 patents and patent applications worldwide.
March 2, 2021
RegMed Investors’ (RMi) closing bell: some say volatility has resurfaced, I had said it never left
March 2, 2021
RegMed Investors’ (RMi) pre-open: a case of investing interruptus from the previous session?
March 1, 2021
RegMed Investors’ (RMi) closing bell: sector rebounds after a tough February
March 1, 2021
RegMed Investors’ (RMi) pre-open: a new month, rotating with a sentiment boost
February 26, 2021
RegMed Investors’ (RMi) closing bell: telling a sector story with daily data
February 26, 2021
RegMed Investors’ (RMi) pre-open: momentum and resistance, the cause and causation of the month’s last session
February 24, 2021
RegMed Investors’ (RMi) closing bell: volatility provides a comeback
February 24, 2021
RegMed Investors’ (RMi) pre-open: a bounce, a pounce or just an ounce of upside needed
35 companies, 1 interpreter!
Insight, foresight and recommendation
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors